Wednesday, July 8, 2026

pharma · Acne Vulgaris · Pruritus · VYNE

VYNE Therapeutics

Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa,

520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
Status
Public
HQ
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
Founded
2003
Employees
47
Programs
30
Drugs
16
Patents
7
Clinical program

Comparator: MK0594 5 mg/day

Phase 2 · small molecule · Alcohol Dependence

Comparator: MK0594 5 mg/day for Alcohol Dependence is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).

← All VYNE Therapeutics projects Phase 2 small molecule terminated

Internal code 0594-020

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
VYNE Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Alcohol Dependence
Status
terminated
Trials
1